Interaksi Desloratadin

Desloratadin (Clarinex), golongan antihistamin, memiliki 121 interaksi terdokumentasi dalam label FDA dan lembar fakta yang kami indeks: 7 mayor, 29 moderat, 39 minor, dan 46 dengan label yang melaporkan tidak ada interaksi bermakna. Setiap entri di bawah ini mengutip kalimat yang mendasarinya. Halaman obat ini adalah titik awal, bukan putusan untuk situasi Anda.

Interaksi dari label

Interaksi mayor (7)

  • DoksilaminantihistaminMayor

    …glaucoma • trouble urinating due to an enlarged prostate gland Ask a doctor or pharmacist before use if you are taking • a sedative or any other sleep-aid • tranquilizers • any other antihistamines • any other drugs When using this product • avoid alcoholic beverages • do not drive a motor vehicle or operate machinery • take only at bedtime Stop use and ask a doctor… (label Doksilamin, Peringatan)

  • Doksilamin dan piridoksinantihistaminMayor

    …hydrochloride delayed-release tablets are contraindicated in women with any of the following conditions: Known hypersensitivity to doxylamine succinate, other ethanolamine derivative antihistamines, pyridoxine hydrochloride or any inactive ingredient in the formulation Monoamine oxidase (MAO) inhibitors intensify and prolong the adverse central nervous system effects… (label Doksilamin dan piridoksin, Kontraindikasi)

  • LoratadinantihistaminMayor

    CLARINEX Tablets, RediTabs, and Oral Solution are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [see Warnings and Precautions (5.1) and Adverse Reactions (6.2) ]. (label Desloratadin, Kontraindikasi)

  • Moeksiprilpenghambat ACEMayor

    None of the cases were considered life-threatening and all resolved either without treatment or with medication (antihistamines or glucocorticoids). (label Moeksipril, Peringatan)

  • PerfenazinantipsikotikMayor

    …contraindicated in comatose or greatly obtunded patients and in patients receiving large doses of central nervous system depressants (barbiturates, alcohol, narcotics, analgesics, or antihistamines); in the presence of existing blood dyscrasias, bone marrow depression, or liver damage; and in patients who have shown hypersensitivity to perphenazine products, their… (label Perfenazin, Kontraindikasi)

  • Pitolisantobat yang memperpanjang interval QTMayor

    Prevention or Management: Avoid centrally acting H1 receptor antagonists. (label Pitolisant, Interaksi obat)

  • Tranilsiprominpenghambat MAOMayor

    These medicines are in some cold, hay fever or weight-loss medicines. sympathomimetic herbal medicines or dietary supplements antihistamines (allergy medicines) triptans buspirone carbamazepine dextromethorphan dopamine hydroxytryptophan and tryptophan levodopa and methyldopa meperidine rasagline resperine s-adenosyl-L-methionine (SAM-e) tapentadol tetrabenazin… (label Tranilsipromin, Peringatan kotak hitam)

Interaksi moderat (29)

  • AlemtuzumabimunosupresanModerat

    Premedicate patients with an antihistamine and acetaminophen prior to each dose. (label Alemtuzumab, Peringatan dan perhatian)

  • AliskirenantihipertensiModerat

    Patients who experience these effects, even without respiratory distress, require prolonged observation and appropriate monitoring measures since treatment with antihistamines and corticosteroids may not be sufficient to prevent respiratory involvement. (label Aliskiren, Peringatan dan perhatian)

  • AlpelisibModerat

    If a SCAR is not confirmed, VIJOICE may require dose modifications, topical or systemic corticosteroids, or oral antihistamine treatment as described in Table 4 [see Dosage and Administration (2.5)] . (label Alpelisib, Peringatan dan perhatian)

  • Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. (label Bendamustin, Peringatan dan perhatian)

  • Budesonid dan formoterolkortikosteroidModerat

    In clinical studies, concurrent administration of budesonide and formoterol fumarate dihydrate and other drugs, such as short-acting beta 2 -agonists, intranasal corticosteroids, and antihistamines/decongestants has not resulted in an increased frequency of adverse reactions. (label Budesonid dan formoterol, Interaksi obat)

  • DiazepambenzodiazepinModerat

    …be given to the pharmacology of the agents employed particularly with compounds that may potentiate or be potentiated by the action of Valium, such as phenothiazines, antipsychotics, anxiolytics/sedatives, hypnotics, anticonvulsants, narcotic analgesics, anesthetics, sedative antihistamines, narcotics, barbiturates, MAO inhibitors and other antidepressants. (label Diazepam, Interaksi obat)

  • Other Drugs that Cause CNS Depression The concurrent use of diphenoxylate hydrochloride and atropine sulfate with other drugs that cause CNS depression (e.g., barbiturates, benzodiazepines, opioids, buspirone, antihistamines, muscle relaxants), may potentiate the effects of diphenoxylate hydrochloride and atropine sulfate (see WARNINGS ). (label Difenoksilat dan atropin, Interaksi obat)

  • DisikloverinantikolinergikModerat

    …following agents may increase certain actions or side effects of anticholinergic drugs including dicyclomine hydrochloride: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents,… (label Disikloverin, Interaksi obat)

  • Doksepinantidepresan trisiklikModerat

    Potential additive effects when used in combination with CNS depressants or sedating antihistamines. (label Doksepin, Peringatan dan perhatian)

  • DronabinolkanabinoidModerat

    Concomitant use of other drugs that cause dizziness, confusion, sedation, or somnolence such as CNS depressants may increase this effect (e.g., barbiturates, benzodiazepines, lithium, opioids, buspirone, scopolamine, antihistamines, tricyclic antidepressants, other anticholinergic agents, and muscle relaxants). (label Dronabinol, Peringatan dan perhatian)

  • Droperidolantagonis dopaminModerat

    Possible pharmacodynamic interactions can occur between droperidol and potentially arrhythmogenic agents such as class I or III antiarrhythmics, antihistamines that prolong the QT interval, antimalarials, calcium channel blockers, neuroleptics that prolong the QT interval, and antidepressants. (label Droperidol, Interaksi obat)

  • EfavirenzantiretroviralModerat

    Prophylaxis with appropriate antihistamines before initiating therapy with efavirenz in pediatric patients should be considered. (label Efavirenz, Peringatan dan perhatian)

  • EpinefrinsimpatomimetikModerat

    …arrhythmias [see Warnings and Precautions (5.6) and Adverse Reactions (6) ]. β-blockers, such as propranolol Cyclopropane or halogenated hydrocarbon anesthetics, such as halothane Antihistamines Thyroid hormones Diuretics Cardiac glycosides, such as digitalis glycosides Quinidine Drugs potentiating hypokalemic effects of epinephrine • Potassium depleting diuretics… (label Epinefrin, Interaksi obat)

  • EstazolambenzodiazepinModerat

    The action of the benzodiazepines may be potentiated by anticonvulsants, antihistamines, alcohol, barbiturates, monoamine oxidase inhibitors, narcotics, phenothiazines, psychotropic medications, or other drugs that produce CNS depression. (label Estazolam, Interaksi obat)

  • • Large doses of salicylates, cortisone, adrenocorticotropic hormone (ACTH), estrogens or antihistamines may require larger amounts of hyaluronidase for equivalent dispersing effect ( 7.4 ) (label Hialuronidase, Interaksi obat)

  • Imatinibpenghambat CYP3A4Moderat

    In these instances, Gleevec was resumed at a dose lower than that at which the reaction occurred and some patients also received concomitant treatment with corticosteroids or antihistamines. (label Imatinib, Peringatan dan perhatian)

  • InfliksimabimunosupresanModerat

    Medications for the treatment of hypersensitivity reactions (e.g., acetaminophen, antihistamines, corticosteroids and/or epinephrine) should be available for immediate use in the event of a reaction [see Dosage and Administration (2.10) and Adverse Reactions (6.1) ] . (label Infliksimab, Peringatan dan perhatian)

  • Isoprenalinagonis beta-adrenergikModerat

    Drugs that may potentiate clinical response of Isoproterenol Clinical Impact The effects of isoproterenol may be potentiated by tricyclic antidepressants, monoamine oxidase inhibitors, levothyroxine sodium, and certain antihistamines, notably chlorpheniramine, tripelennamine, and diphenhydramine. (label Isoprenalin, Interaksi obat)

  • Lisinopril dan hidroklorotiazidpenghambat ACEModerat

    Even in those instances where swelling of only the tongue is involved, without respiratory distress, patients may require prolonged observation since treatment with antihistamines and corticosteroids may not be sufficient. (label Lisinopril dan hidroklorotiazid, Peringatan)

  • In patients who experience mild or moderate IRRs, consider premedications, including antihistamines, corticosteroids, and antipyretics. (label Margetuksimab, Peringatan dan perhatian)

  • MeflokuinantimalariaModerat

    Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (label Meflokuin, Interaksi obat)

  • Anaphylactic Shock and Hypersensitivity Reactions: Premedicate all patients with a combination of an H1-antihistamine, an H2 blocker, and a leukotriene inhibitor prior to each APHEXDA dose. (label Motiksafortid, Peringatan dan perhatian)

  • OfloksasinfluorokuinolonModerat

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated (see PRECAUTIONS and ADVERSE REACTIONS ). (label Ofloksasin, Peringatan)

  • OkrelizumabimunosupresanModerat

    In multiple sclerosis (MS) clinical trials, all adult and pediatric patients who were treated with OCREVUS received premedication with methylprednisolone (or an equivalent steroid), and may have also received an antihistamine (all pediatric patients) and/or an analgesic/antipyretic to reduce the risk of infusion reactions prior to each infusion. (label Okrelizumab, Peringatan dan perhatian)

  • SkopolaminantikolinergikModerat

    Concomitant use of other drugs that cause central nervous system (CNS) adverse reactions (e.g., alcohol, sedatives, hypnotics, opiates, and anxiolytics) or have anticholinergic properties (e.g., other belladonna alkaloids, sedating antihistamines, meclizine, tricyclic antidepressants, and muscle relaxants) may increase this effect [see Drug Interactions ( 7.1 )] . (label Skopolamin, Peringatan dan perhatian)

  • TemazepambenzodiazepinModerat

    The benzodiazepines, including temazepam, produce additive CNS-depressant effects when co-administered with other CNS depressants such as alcohol, barbiturates, antipsychotics, sedative/hypnotics, anxiolytics, antidepressants, narcotic analgesics, sedative antihistamines, anticonvulsants, and anesthetics. (label Temazepam, Interaksi obat)

  • TORISEL should be used with caution in patients with known hypersensitivity to an antihistamine, or patients who cannot receive an antihistamine for other medical reasons. (label Temsirolimus, Peringatan dan perhatian)

  • TiotropiumantikolinergikModerat

    Concomitant Respiratory Medications SPIRIVA RESPIMAT has been used concomitantly with short-acting and long-acting sympathomimetic (beta-agonists) bronchodilators, methylxanthines, oral and inhaled steroids, antihistamines, mucolytics, leukotriene modifiers, cromones, and anti-IgE treatment without increases in adverse reactions. (label Tiotropium, Interaksi obat)

  • Prior to the first BIZENGRI infusion, premedicate with a corticosteroid, an H1 antihistamine and acetaminophen to reduce the risk of IRRs [see Dosage and Administration (2.4) ]. (label Zenokutuzumab, Peringatan dan perhatian)

Penyebutan minor (39)

  • If signs of hypersensitivity occur, e.g. anaphylactoid reaction or angioedema develops, discontinue the Activase infusion and promptly institute appropriate therapy (e.g., antihistamines, intravenous corticosteroids, epinephrine). (label Alteplase, Peringatan dan perhatian)

  • Benazeprilpenghambat ACEMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Benazepril, Peringatan dan perhatian)

  • Discontinue in patients who develop a severe infusion-related reaction and administer appropriate medical therapy (e.g., epinephrine, corticosteroids, intravenous antihistamines, bronchodilators and/or oxygen). (label Bevasizumab, Peringatan dan perhatian)

  • Dekstroamfetaminstimulan SSPMinor

    Antihistamines Amphetamines may counteract the sedative effect of antihistamines. (label Dekstroamfetamin, Interaksi obat)

  • Appropriate antihistamines and/or corticosteroids may improve the tolerability and hasten the resolution of rash. (label Efavirenz, lamivudin, dan tenofovir, Peringatan dan perhatian)

  • Enalaprilpenghambat ACEMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Enalapril, Peringatan dan perhatian)

  • In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. (label Enalapril dan hidroklorotiazid, Peringatan)

  • Enalaprilatpenghambat ACEMinor

    In instances where swelling has been confined to the face and lips the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. (label Enalaprilat, Peringatan)

  • Eritromisinantibiotik makrolidaMinor

    Erythromycin has been reported to significantly alter the metabolism of the nonsedating antihistamines terfenadine and astemizole when taken concomitantly. (label Eritromisin, Interaksi obat)

  • FlunisolidkortikosteroidMinor

    Instead, nasal vasoconstrictors or oral antihistamines may be needed until the effects of flunisolide are fully manifested. (label Flunisolid, Perhatian)

  • FluoksetinSSRIMinor

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (label Fluoksetin, Peringatan dan perhatian)

  • HeparinantikoagulanMinor

    Other Interactions Digitalis, tetracyclines, nicotine, or antihistamines, or intravenous nitroglycerin may partially counteract the anticoagulant action of heparin sodium. (label Heparin, Interaksi obat)

  • Antihistamines and/or aspirin have been used for most mild to moderate cases. (label Ivermektin, Peringatan)

  • Kanabidiol (obat resep)antikonvulsanMinor

    Some subjects in the EPIDIOLEX clinical trials had pruritus, erythema, and angioedema requiring treatment, including corticosteroids and antihistamines. (label Kanabidiol (obat resep), Peringatan dan perhatian)

  • KarbamazepinantikonvulsanMinor

    CNS depressants include: alcohol, opioid analgesics, benzodiazepines, tricyclic antidepressants, sedative/hypnotics, anticonvulsants, antipsychotics, antihistamines, anticholinergics, alpha and beta blockers, general anesthetics, muscle relaxants, and illicit CNS depressants. (label Karbamazepin, Interaksi obat)

  • Kuinaprilpenghambat ACEMinor

    In instances where swelling is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. (label Kuinapril, Peringatan)

  • In instances where swelling is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. (label Kuinapril dan hidroklorotiazid, Peringatan)

  • LevofloksasinfluorokuinolonMinor

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other resuscitative measures, including oxygen, intravenous fluids, antihistamines, corticosteroids, pressor amines, and airway management, as clinically indicated [see Adverse Reactions ( 6 ) and Patient Counseling Information ( 17 )] . (label Levofloksasin, Peringatan dan perhatian)

  • Lisinoprilpenghambat ACEMinor

    Symptoms have not been relieved by antihistamines in these situations. (label Lisinopril, Peringatan dan perhatian)

  • The infusion should be terminated immediately, followed by the administration of volume expanders, pressor agents, corticosteroids, or antihistamines at the discretion of the physician. (label Melfalan, Peringatan)

  • Oksasilinantibiotik penisilinMinor

    If an allergic reaction occurs, the drug should be discontinued and the patient should receive supportive treatment, e.g. , artificial maintenance of ventilation, pressor amines, antihistamines, and corticosteroids. (label Oksasilin, Peringatan)

  • Olanzapin dan fluoksetinantipsikotikMinor

    Most patients improved promptly with discontinuation of fluoxetine and/or adjunctive treatment with antihistamines or steroids, and all patients experiencing these reactions were reported to recover completely. (label Olanzapin dan fluoksetin, Peringatan dan perhatian)

  • Pruritus and early rash may often be controlled by the concomitant administration of antihistamines. (label Penisilamin, Perhatian)

  • PerampanelantikonvulsanMinor

    Patients should limit activity until they have experience with concomitant use of CNS depressants (e.g., benzodiazepines, narcotics, barbiturates, sedating antihistamines). (label Perampanel, Interaksi obat)

  • RituksimabimunosupresanMinor

    Premedicate patients with an antihistamine and acetaminophen prior to dosing. (label Rituksimab, Peringatan dan perhatian)

  • Sakubitril dan valsartanpenghambat reseptor angiotensin II (ARB)Minor

    In cases of confirmed angioedema where swelling has been confined to the face and lips, the condition has generally resolved without treatment, although antihistamines have been useful in relieving symptoms. (label Sakubitril dan valsartan, Peringatan dan perhatian)

  • SefadroksilsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefadroksil, Peringatan dan perhatian)

  • SefaklorsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefaklor, Peringatan)

  • SefdinirsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefdinir, Peringatan)

  • SefotetansefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefotetan, Peringatan)

  • SefpodoksimsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINE, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefpodoksim, Peringatan)

  • SefprozilsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, INTRAVENOUS FLUIDS, INTRAVENOUS ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Sefprozil, Peringatan)

  • SeftazidimsefalosporinMinor

    SERIOUS ACUTE HYPERSENSITIVITY REACTIONS MAY REQUIRE TREATMENT WITH EPINEPHRINE AND OTHER EMERGENCY MEASURES, INCLUDING OXYGEN, IV FLUIDS, IV ANTIHISTAMINES, CORTICOSTEROIDS, PRESSOR AMINES, AND AIRWAY MANAGEMENT, AS CLINICALLY INDICATED. (label Seftazidim, Peringatan)

  • SeftriaksonsefalosporinMinor

    Serious acute hypersensitivity reactions may require treatment with epinephrine and other emergency measures including oxygen, corticosteroids, intravenous fluids, intravenous antihistamines, pressor amines, and airway management, as clinically indicated. (label Seftriakson, Peringatan dan perhatian)

  • SiprofloksasinfluorokuinolonMinor

    Serious anaphylactic reactions require immediate emergency treatment with epinephrine and other resuscitation measures, including oxygen, intravenous fluids, intravenous antihistamines, corticosteroids, pressor amines, and airway management, including intubation, as indicated [see Adverse Reactions ( 6.1 , 6.2 )]. (label Siprofloksasin, Peringatan dan perhatian)

  • If symptoms of hypersensitivity occur, initiate appropriate therapy (e.g., antihistamines, corticosteroids, epinephrine). (label Tenekteplase, Peringatan dan perhatian)

  • Trandolaprilpenghambat ACEMinor

    In instances where swelling is confined to the face and lips, the condition generally resolves without treatment; antihistamines may be useful in relieving symptoms. (label Trandolapril, Peringatan)

  • Prior to resumption of trastuzumab infusion, the majority of patients who experienced a severe infusion reaction were pre-medicated with antihistamines and/or corticosteroids. (label Trastuzumab, Peringatan dan perhatian)

  • ZiprasidonantipsikotikMinor

    Most patients improved promptly with adjunctive treatment with antihistamines or steroids and/or upon discontinuation of ziprasidone, and all patients experiencing these reactions were reported to recover completely. (label Ziprasidon, Peringatan dan perhatian)

Tidak ada interaksi bermakna yang dilaporkan (46)

  • AmiodaronantiaritmiaTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Aprepitantpenghambat CYP3A4Tanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • AtazanavirantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Azitromisinantibiotik makrolidaTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • DarunavirantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Darunavir dan kobisistatantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Diltiazempenghambat kanal kalsiumTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • DronedaronantiaritmiaTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • EsitalopramSSRITanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • EverolimusimunosupresanTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Famotidinpenghambat H2Tanpa interaksi

    …safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile… (label Desloratadin, Interaksi obat)

  • Flukonazolantijamur azolTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • FluvoksaminSSRITanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • FosamprenavirantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Fosaprepitantpenghambat CYP3A4Tanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Ibuprofen dan famotidinOAINSTanpa interaksi

    …safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile… (label Desloratadin, Interaksi obat)

  • IsoniazidantibiotikTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Itrakonazolantijamur azolTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Ivakaftorpenghambat CYP3A4Tanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Ketokonazolantijamur azolTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Klaritromisinantibiotik makrolidaTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • LenakapavirantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Lopinavir dan ritonavirantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Mifepristonpenghambat CYP3A4Tanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Mirabegronagonis beta-adrenergikTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • NefazodonantidepresanTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Nirmatrelvir dan ritonavirantivirusTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Nizatidinpenghambat H2Tanpa interaksi

    …safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile… (label Desloratadin, Interaksi obat)

  • Palbosiklibpenghambat CYP3A4Tanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • ParoksetinSSRITanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • Posakonazolantijamur azolTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Ranitidinpenghambat H2Tanpa interaksi

    …safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H2-receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile… (label Desloratadin, Interaksi obat)

  • Ranolazinobat yang memperpanjang interval QTTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • RitonavirantiretroviralTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Ropinirolagonis dopaminTanpa interaksi

    Commonly Administered Drugs: Population analysis showed that commonly administered drugs (e.g., selegiline, amantadine, tricyclic antidepressants, benzodiazepines, ibuprofen, thiazides, antihistamines, anticholinergics) did not affect the clearance of ropinirole. (label Ropinirol, Interaksi obat)

  • SenobamatantikonvulsanTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • SertralinSSRITanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • SiklosporinimunosupresanTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Simetidinpenghambat H2Tanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • SitalopramSSRITanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • Suvoreksantsedatif-hipnotikTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • TikagrelorantiplateletTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • Verapamilpenghambat kanal kalsiumTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

  • VilazodonSSRITanpa interaksi

    …changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes… (label Desloratadin, Interaksi obat)

  • Vorikonazolantijamur azolTanpa interaksi

    Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [See Clinical Pharmacology (12.3) .]… (label Desloratadin, Interaksi obat)

Periksa Desloratadin terhadap semua yang Anda gunakan. Tambahkan seluruh daftar Anda; setiap pasangan diperiksa sekaligus.

Buka di pemeriksa

Bukan nasihat medis. Tingkat keparahan mencerminkan kata-kata dalam label, bukan keadaan Anda. Tanda “mayor” bisa merupakan hal yang rutin di bawah pengawasan, dan tanda “minor” bisa menjadi penting pada dosis tinggi. Tanyakan kepada apoteker.